Auto-generated event page

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

Castle will share new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.

Score 41 low confidence 1 source posts Updated Mar 4, 2026, 9:45 PM UTC

Track This Event Open Event in App More Signal Pages

Cluster sources

Newest source rows first.

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

GlobeNewswire Public Companies • Mar 4, 2026, 9:30 PM UTC

Entity focus

Direct link to post

https://pushme.site/signals/193374-castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanoma-s-?utm_source=signal-193374&utm_medium=social&utm_campaign=signal-pages&utm_content=hero

Quick distribution loop

Step 1

Post this live link in threads where users ask how to monitor this event.

Step 2

Point readers to "Track This Event" for immediate conversion into an alert.

Step 3

Reuse entity keywords from this page for targeted follow-up replies.

Back to signal pages Open query hub